Zobrazeno 1 - 3
of 3
pro vyhledávání: '"H J, Thurston"'
Autor:
Christopher J. Hawkey, A. J. Kivitz, T. Schimansky, Alberto Gimona, S. Nayiager, H. J. Thurston
Publikováno v:
Alimentary Pharmacology & Therapeutics. 19:1189-1198
Summary Background : Lumiracoxib (Prexige; Novartis Pharma AG, Basel, Switzerland) is a cyclooxygenase-2 selective inhibitor associated with improved gastrointestinal safety compared with nonsteroidal anti-inflammatory drugs, in patients with osteoar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abdb57d72cb540ed6751bdf8a1b78ca9
https://doi.org/10.1111/j.1365-2036.2004.01956.x
https://doi.org/10.1111/j.1365-2036.2004.01956.x
Autor:
K A, Papp, R G, Langley, B, Sigurgeirsson, M, Abe, D R, Baker, P, Konno, S, Haemmerle, H J, Thurston, C, Papavassilis, H B, Richards
Publikováno v:
The British journal of dermatology. 168(2)
Conventional systemic therapies for plaque psoriasis have not fully met the needs of patients, and although current biologic treatments are generally well tolerated, concerns exist with respect to long-term safety. Interleukin (IL)-17A is believed to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::350f0d6389fe410d38ef275c00857a3b
https://pubmed.ncbi.nlm.nih.gov/23106107
https://pubmed.ncbi.nlm.nih.gov/23106107
Publikováno v:
Alimentary pharmacologytherapeutics. 19(11)
Lumiracoxib (Prexige; Novartis Pharma AG, Basel, Switzerland) is a cyclooxygenase-2 selective inhibitor associated with improved gastrointestinal safety compared with nonsteroidal anti-inflammatory drugs, in patients with osteoarthritis.To compare th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::6912cd4922584a0723f7ca3911133b61
https://pubmed.ncbi.nlm.nih.gov/15153172
https://pubmed.ncbi.nlm.nih.gov/15153172